High Tide Guides Q3 Revenue to C$195M–C$200M, Above Consensus, with Record German Cannabis Distribution
HITI is trading near its 52-week low of $2.02 (9.4% above the low) on light trading volume (0.3× avg).
Summary
High Tide issued preliminary Q3 2026 guidance with revenue of C$195M–C$200M, gross profit of C$51M–C$53.5M, and Adjusted EBITDA of C$15.2M–C$16.5M — all above analyst consensus. The company also reported record German medical cannabis distribution of over 10 tonnes and a return to positive same-store sales in Canada.
Key Events · Earnings and Guidance · HITI
-
Q3 Guidance Beats Across the Board
Preliminary Q3 2026 revenue of C$195M–C$200M, gross profit of C$51M–C$53.5M, and Adjusted EBITDA of C$15.2M–C$16.5M — all above the highest analyst estimate.
-
Record German Cannabis Distribution
Remexian Pharma GmbH shipped over 10 tonnes of medical cannabis flower in Q3, up 33% sequentially and 60% year-over-year, accelerating its German market position.
-
Canadian Same-Store Sales Turn Positive
Canadian bricks-and-mortar same-store sales returned to positive year-over-year growth in June and remained positive in July, contrasting with broader market trends.
-
Full Results Expected September 14
The company plans to release full Q3 financial and operational results on Monday, September 14, 2026, after market close, with a conference call the following morning.
Analysis · HITI · Trade & Services
High Tide pre-announced preliminary Q3 2026 results that beat analyst expectations across all key metrics — revenue, gross profit, and Adjusted EBITDA — with the low end of guidance exceeding the highest Street estimate. The company also disclosed a record 10 tonnes of medical cannabis distributed through its German subsidiary, up 33% sequentially, and a return to positive same-store sales in Canada. This signals accelerating operating momentum and suggests the market has not yet priced in the strength of the business. The guidance comes ahead of full results on September 14, 2026, and reinforces the earnings power of the company's dual Canadian retail and German medical cannabis engines.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HITI was trading at $2.21 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $188.9M. The 52-week trading range was $2.02 to $4.06. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.